女性雄性禿 (FPHL)

Fphl

共 2 種介入成分有評級——按證據強度從高到低排序

🔬 實證評級速查
🔵 A 中度證據螺內酯 / 安達通 × 女性雄性禿 (FPHL)

白話說：證據中等，有一定的支持。

證據分數 72 分（滿分 100） 　·　發布狀態：可參考，但附帶但書

🇹🇼 台灣有獨立規範
這樣判讀，是參考了這些單位：
  • 第三方營養資料庫（國際）
    展開原文引用
    「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」
  • US FDA 態度：支持
    展開原文引用
    「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」
  • EU EFSA 態度：支持
    展開原文引用
    「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。 產製日期 2026-06-09 ·　版本 v4。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查
🟡 B 初步證據口服低劑量 Minoxidil × 女性雄性禿 (FPHL)

白話說：有初步證據，但研究規模還小，別當成定論。

證據分數 69 分（滿分 100） 　·　發布狀態：可參考，但附帶但書

🇹🇼 台灣有獨立規範
這樣判讀，是參考了這些單位：
  • 第三方營養資料庫（國際）
    展開原文引用
    「Low-dose oral minoxidil (LDOM, 0.25-5mg/day) is an off-label repurposing of the antihypertensive drug Loniten for androgenetic alopecia and other hair loss disorders, gaining mainstream dermatology ad」
  • US FDA 態度：持保留
    展開原文引用
    「BOXED WARNING: 'Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent ta…」
  • EU EFSA 態度：持保留
    展開原文引用
    「Minoxidil and its salts must not be used in cosmetic products because of their antihypertensive activity. Minoxidil absorption after scalp application could lead to systemic effects. [Minoxidil is] a peripheral vasodilatator acting on vascular smooth muscle cells, used as a drug in the management of severe hypertension. [The substance is] cardiotoxic in long term oral studies.」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。 產製日期 2026-06-09 ·　版本 v4。本評級僅供衛教參考，不取代醫師診斷與處方。 · 📊 證據資料庫原始頁面